F. Zannad

Publications1,215
h-index113
Citations103,121
Highly Influential Citations2,398
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • J. McMurray
  • 1,612 Publications • 158,447 Citations
  • S. Solomon
  • 1,405 Publications • 101,842 Citations
  • P. Rossignol
  • 562 Publications • 12,584 Citations
  • B. Pitt
  • 1,142 Publications • 92,686 Citations
  • Publications
  • Influence
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European…
TLDR
A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People and the Effect of Potentially Modifiable Risk Factors associated with Myocardial Infarction is presented. Expand
2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European…
2007 Guidelines for the Management of Arterial Hypertension : The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of… Expand
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.
TLDR
Blockade of aldosterone receptors by spironolactone, in addition to standard therapy, substantially reduces the risk of both morbidity and death among patients with severe heart failure. Expand
European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012)
TLDR
Atherosclerotic cardiovascular disease is a chronic disorder developing insidiously thoughout life and usually progressing to an advanced stage by the time symptoms occur, thereby remaining the leading somatic cause of loss of productivity. Expand
Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
TLDR
Among patients with type 2 diabetes who had had a recent acute coronary syndrome, the rates of major adverse cardiovascular events were not increased with the DPP-4 inhibitor alogliptin as compared with placebo. Expand
Eplerenone in patients with systolic heart failure and mild symptoms.
TLDR
Eplerenone, as compared with placebo, reduced both the risk of death and therisk of hospitalization among patients with systolic heart failure and mild symptoms. Expand
Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction
TLDR
The addition of eplerenone to optimal medical therapy reduces morbidity and mortality among patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure. Expand
Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial.
TLDR
Exercise training was associated with modest significant reductions for both all-cause mortality or hospitalization and cardiovascular mortality or heart failure hospitalization, and in key secondary clinical end points. Expand
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
TLDR
The addition of eplerenone to optimal medical therapy reduces morbidity and mortality among patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure. Expand
...
1
2
3
4
5
...